DERR-2025-009158

Response to Comments Groundwater RAP Addendum
-102 July 7,

July 7, 2025

Ms. Leigh Anderson
Utah Department of Environmental Quality
Division of Environmental Response and Remediation
195 North 1950 West
Salt Lake City, UT 84116

Re: Response to Comments: October 2024 Groundwater Remedial Action Plan
Addendum and September 2024 Plume Analytics Report
Former General Electric Facility
130 East 1100 North
North Salt Lake, Utah
VCP No. C-102
WSP Project No. US0041939.2677

Dear Ms. Anderson:

WSP USA, Inc. (WSP) on behalf of GE Vernova is providing this response to comments
received from the Utah Department of Environmental Quality (UDEQ), Division of Environmental
Response and Remediation (DERR) on the Groundwater Remedial Action Plan Addendum
(dated October 22, 2024) for the former GE Vernova facility located at 130 East 1100 North, in
North Salt Lake, Utah (Site). In addition, this document addresses comments received on the
September 2024 Plume Analytics Report (dated November 1, 2024) for the Site.

The UDEQ DERR comments, dated February 18, 2025, are presented below, and followed by
GE Vernova’s response. It is clear based on DERR’s Specific Comment 1, and the responses
provided, that the process to achieve risk-based closure at this Site remains unresolved and
further discussion is warranted.

GE maintains MNA as the appropriate remedial action for chlorinated VOCs and monitoring as
the appropriate action selected to address 1,4-dioxane. Alternative remedial actions are neither
cost-effective nor technically viable for 1,4-dioxane.

DERR Review Comments on the Groundwater RAP Addendum
Specific Comments:

1. Page 2, Objective and Page 8, Proposed Performance Objectives: The DERR cannot
accept the proposed Monitored Natural Attenuation (MNA) remedy at this time for the
reasons outlined below in this comment. Please revise the plan to propose a remedy to
WSP USA Inc.
216 Centerview Drive
Suite 300
Brentwood, TN 37027
[phone]

wsp.com

Response to Comments Groundwater RAP Addendum
-102 July 7,
meet the Performance Objectives and goals in the Groundwater RAP Addendum.

a. The historical groundwater data set does not demonstrate a clear and meaningful
trend of decreasing contaminant mass and/or concentration over time in MW-3
and MW-17. These locations are considered one of several appropriate monitoring
points to gauge the effectiveness of MNA.

Response: After discussions with the DERR on the use of MNA as the selected
groundwater remedy for the Site, submittal of the initial Groundwater RAP Addendum in
July 2024 which identified MNA as the selected remedy for groundwater, discussion on
the RAP Addendum with the DERR in August 2024, and revision and resubmittal of the
RAP Addendum in October 2024 to address the DERR’s stated concerns, the DERR
now indicates there is insufficient evidence to document that natural attenuation is
occurring and thus MNA cannot be the selected remedy for the Site.

The Plume Analytics reports that have been submitted to the DERR on a regular basis
have provided strong documentation of the natural attenuation and degradation of the
chlorinated volatile organic compounds (VOCs) at the Site. The non-chlorinated VOC,
1,4-dioxane, was shown to have migrated off-site at low-level concentrations which were
generally detected above the screening level of 0.46 µg/L (WSP, Groundwater Plume
Analytics® Report, November 2024 and March 2025).

Although it is acknowledged that the September 2024 monitoring event was associated
with higher concentrations of cis-1,2-dichloroethene (cis-1,2-DCE) at MW-17 (110 µg/L)
and of 1,4-dioxane at MW-3 (88 µg/L) and MW-17 (17 µg/L), the Utah regulations
specifically note that that “[c]onsideration will be given to naturally occurring variations in
groundwater contaminant concentrations, natural groundwater flow, and dispersion”.1
During the March 2025 monitoring event, the concentration of cis-1,2-DCE at MW-17
decreased approximately 51 percent to 54 µg/L. The concentration of 1,4-dioxane at
MW-3 decreased approximately 33 percent to 59 µg/L, and at MW-17, the concentration
of 1,4-dioxane decreased approximately 41 percent to 10 µg/L.

In the June 2024 Technical Memorandum on the Potential Risk Associated with 1,4-
Dioxane in groundwater, it was demonstrated there was no risk associated with the on-
site groundwater, and off-site groundwater with 1,4-dioxane concentrations were
associated with a residential cancer risk at the midpoint of the acceptable target cancer
risk range if groundwater were used as a potable water supply. There are no residential
receptors located off-site and shallow groundwater associated with the off-site detections
of 1,4-dioxane is not used as a source of water supply. The off-site risk associated with
the potential vapor intrusion of 1,4-dioxane to indoor air was acceptable. The March
2025 groundwater data associated with the off-site monitoring wells had similar

1 Utah Office of Administrative Rules, Cleanup Action and Risk-Based Closure Standards, Principles of
Non-Degradation, R-315-101-3(a).

Response to Comments Groundwater RAP Addendum
-102 July 7,
concentrations of 1,4-dioxane with analytical results ranging from non-detect to 4 µg/L
(off-site MW-A2).

In response to DERR Comment 8 below, GE Vernova will continue to monitor off-site
groundwater for the presence of 1,4-dioxane for a minimum of two years (four semi-
annual events starting with the March 2025 event) to determine additional monitoring
requirements, or if the off-site groundwater monitoring program can be terminated.
Although the presence of chlorinated VOCs in off-site groundwater has already been
addressed and documented to be associated with an off-site release that is not
associated with the former GE Vernova Facility, in accordance with the approved off-site
groundwater monitoring program, select wells will also continue to be monitored for
chlorinated VOCs.

The remaining response presented here for Comment 1a focuses on 1,4-dioxane. The
specific concentrations of VOCs in groundwater at the Site are discussed in response to
Comment 1b (below).

Evaluation of the on-site groundwater data indicates that during the last ten 2
groundwater monitoring events, 1,4-dioxane has only been detected at concentrations
above the Performance Objective of 46 micrograms per liter (µg/L) at MW-3. Detected
concentrations of 1,4-dioxane at the other monitoring wells present at the Site, including
at the property boundary, are below the Performance Objective. In accordance with the
Utah Code for the Voluntary Cleanup Program 3 at 19-8-110(5), there is flexibility built
into the rules to allow the DERR to not require removal or remedy of all discharges,
releases, etc., as quoted below:

“After considering the proposed future use of the property that is the subject of
the agreement, the executive director may approve work plans and reports
submitted under this section that do not require removal or remedy of all
discharges, releases, and threatened releases on the property if the applicant's
response actions under the agreement:
(a) will be completed in a manner that protects human health and the
environment;
(b) will not cause, contribute to, or exacerbate discharges, releases, or
threatened releases on the property that are not required to be removed
or remedied under the work plan; and
(c) will not interfere with or substantially increase the costs of response
actions to address any remaining discharges, releases, or threatened
releases resulting from releases initially generated on the property.”

2 USEPA’s ProUCL User’s Guide (2022) recommends ten sampling points for the calculation of a 95
percent upper confidence limit (UCL).
3 19-8-110, Voluntary cleanup work plans and reports

Response to Comments Groundwater RAP Addendum
-102 July 7,
As noted in the Groundwater RAP Addendum and discussed in previous submittals, the
constituents of concern (COCs) in shallow groundwater do not have the potential to
migrate vertically to deeper groundwater that is used as a source of potable water supply
(i.e., the municipal well). There are no residential receptors downgradient of the Site and
the Site is currently vacant. The only potentially complete migration pathway associated
with the Site and downgradient locations is considered to be the potential for vapor
intrusion from groundwater to indoor air, and the 1,4-dioxane concentrations in both on-
site and off-site groundwater were demonstrated in the RAP Addendum to be well below
the corresponding residential and industrial vapor intrusion screening levels (VISLs). In
addition, the environmental covenant to be placed on the Site will preclude future
residential development and, with the use of engineering and other site administrative
controls placed upon the property, will also prevent the future use of on-site groundwater
as a source of potable water supply.

With the flexibility incorporated into the Statute, the placement of the environmental
covenant on the property to preclude future residential development and prevent use of
on-site groundwater, and the continuation of the off-site groundwater monitoring program
for a minimum of an additional two years, there does not seem to be a reason for a
costly active remedial alternative (e.g., injection) to address the presence of 1,4-dioxane
at one well (MW-3) when there is no potential for adverse exposure to 1,4-dioxane in
either on-site or off-site groundwater. As noted, the continuation of the off-site
groundwater monitoring program for 1,4-dioxane will allow for the continued evaluation
of 1,4-dioxane concentrations, potential receptors, and corresponding off-site risk
associated with the low-level detections of 1,4-dioxane in off-site groundwater.

For determination of the appropriate corrective action at a site, the regulations (R315-
101-1(c) indicate that the following criteria shall be considered in the order of
importance:
(1) the impact or potential impact of the contamination on human health;
(2) the impact or potential impact of the contamination on the environment;
(3) the technologies available for use in cleanup; and
(4) economic considerations and cost-effectiveness of cleanup options.

GE Vernova has demonstrated that there is no current or reasonably foreseeable future
impact or potential impact to human health or the environment, either on-site or off-site,
due to the presence of 1,4-dioxane in groundwater. It is proposed that in response to this
comment, the Groundwater RAP Addendum be revised to present our current findings
with regard to the cost associated with an “active” remedial alternative to address 1,4-
dioxane in groundwater at MW-3, which given there is no potential for exposure to COCs
in groundwater, is not cost-effective. Therefore, monitoring by itself is considered the
alternative selected to continue to evaluate 1,4-dioxane.

The selection of MNA is appropriate for the chlorinated VOCs which is discussed further
in response to Comment 1b below.

Response to Comments Groundwater RAP Addendum
-102 July 7,

b. The concentrations from the September 2024 groundwater monitoring event were
above the Proposed Performance Objectives in MW-3 (1,4-Dioxane - 88 µg/L compared to
the goal of 46 µg/L) and MW-17 (cis-1,2 DCE - 110 µg/L compared to the goal of 70 µg/L).
Response: As noted in the response to Comment 1a above, the DERR recognizes the
potential for fluctuation in groundwater concentrations [R-315-101-3(a)]. The fluctuations
observed at MW-3 and MW-17 during the September 2024 groundwater monitoring
event are believed to have been associated with the seasonally lower groundwater
levels and its impact on the migration of constituents bound in the smear zone from soil
to groundwater. Data were added to the response to Comment 1a (above) to
demonstrate how concentrations at these two wells have decreased since the
September 2024 event. In addition, the environmental covenant to be placed on the Site
will preclude future residential development and, with the use of engineering and other
site administrative controls placed upon the property, will also prevent the future use of
on-site groundwater as a source of potable water supply.
The need to further discuss the requirement for an active remediation to address 1,4-
dioxane in on-site groundwater was discussed in the response to Comment 1a above.
The concentrations of the VOCs (including 1,4-dioxane) in comparison to the
Performance Objectives are discussed herein along with selection of MNA as an
appropriate remedy for the chlorinated VOCs.
In Comment 7 below, the DERR indicates that compliance with the Performance
Objectives is not on an individual concentration basis but is instead based on the 95
percent upper confidence limit (95% UCL) on the arithmetic average for data collected
from an individual well. This approach is very conservative because if groundwater were
being used, it would be drawn from a radius of influence around a well resulting in the
mixing of groundwater from several, if not many of the wells located at the Site.
Evaluation of the data indicates that only cis-1,2-DCE and 1,4-dioxane have individual
detections within the last 10 events that exceed the Performance Objectives. The well-
specific 95% UCLs for these constituents at applicable monitoring wells are summarized
in Table 1 below. With the exception of cis-1,2-DCE and 1,4-dioxane at MW-3, the 95%
UCLs for all of the individual wells are below the corresponding Performance Objectives.
Specifically, the 95% UCL for cis-1,2-DCE at MW-17 of 59.85 µg/L is below the
Performance Objective of 70 µg/L.
The DERR’s position on the need for an active remedy seems to focus on MW-3 where
the 95% UCLs for cis-1,2-DCE and 1,4-dioxane exceed the corresponding Performance
Objectives. As noted, MW-3 is located on the former facility where there is no current
potential exposure to groundwater and where future potential exposures will be
prevented by the use of the environmental covenant.

Response to Comments Groundwater RAP Addendum
-102 July 7,
Table 1
Performance Objectives in Comparison to Individual Well 95% UCLs
Well Cis-1,2-DCE
95% UCL (µg/L)
1,4-Dioxane
95% UCL (µg/L)
MW-1 NA 0.81
MW-2 58 11
MW-3 88 87
MW-4 NA 17
MW-10 NA 3.6
MW-11 NA 7.3
MW-12 NA 19
MW-13 NA 1.4
MW-15 NA 1.5
MW-16 NA 1.7
MW-17 60 9.9
MW-18 NA 8.4
MW-19 NA 3.9
Performance Objectives: 70 46
NA – not applicable. The well was not evaluated for the referenced constituent as the
concentrations were not of concern for meeting the Performance Objectives (see Attachment 1).

The Groundwater Plume Analytics® Services report for the Site (WSP, March 2025) indicates
that between September 2021 to March 2025, the on-site TCE area in acres was stable, with its
average concentration, and plume mass indicator (lbs) exhibiting decreasing trends with
confidence levels in the regression analyses and Mann-Kendall trends ranging from 97%
(regression analysis and Mann-Kendall trend confidence level for decreasing average
concentration and plume mass indicator) to 99% (Mann-Kendall trend confidence level for
decreasing average TCE concentration). Cis-1,2-DCE, a breakdown product of TCE, shows
stable trends for area, average concentration and mass. The on-site 1,1-DCE plume exhibits a
decreasing trend in average concentration and decreasing/no trend for area or mass. The on-
site 1,1-DCA plume exhibits decreasing trends in area, average concentration, and mass with
confidence levels at 99% for both regression analysis and Mann-Kendall trends. These data
analyses support the continuing MNA of the chlorinated VOCs of concern in Site groundwater.
c. The “Full Plume Area” and “Full Plume Mass Indicator” noted in the groundwater
model for 1,4-Dioxane was greater in September 2024 (10.1 acres and 0.82 lbs,
respectively) as compared to December 2022 (8.2 acres and 0.69 lbs, respectively). This
suggests the overall plume may not be attenuating at a rate necessary to achieve the
project goals. The December 2022 sampling event was one of the first events to include
on and off-site data and provides a reasonable overview of baseline conditions to help
gauge the rate and level of attenuation when compared to current data.

Response: As noted in the responses to the previous comments, the UDERR regulations
acknowledge that there is going to be some fluctuation in groundwater data. The current

Response to Comments Groundwater RAP Addendum
-102 July 7,
Groundwater Plume Analytics® Services report for the Site for March 2025 indicates that
between September 2021 to March 2025 the area of 1,4-dioxane on-site decreased 10 percent,
the average concentration decreased 51 percent, and the mass indicator decreased 56%.

See response to Comment 1a with respect to the need to conduct an active remediation of 1,4-
dioxane in groundwater.

2. Page 8, Proposed Performance Objectives for On-site Groundwater: Please revise the
text to note that the goal of the remedial efforts is to meet the Performance Objectives in
Table 2 and ensure the off-site impacts associated with the site do not pose an
unacceptable risk.

Response: The text under the Proposed Performance Objectives will be revised to
indicate: “The overall remedial objective is to meet the Performance Objectives in Table
2 for on-site groundwater and to ensure the impacts to off-site groundwater do not pose
an unacceptable risk. The Performance Objectives for each COC, the Basis of each
Performance Objective, and the range of detected concentrations for each COC are
summarized below“.
3. Page 8, Proposed Performance Objectives for On-site Groundwater: Arsenic
concentrations will be screened against the MCL. Please revise the text.
Response: Table 2 will be revised to identify the Performance Objective for arsenic of
10 micrograms per liter (µg/L) with the Basis of Performance Objective identified as the
Maximum Contaminant Level (MCL).
4. Page 10, Third Bullet: Please remove the wording “other than the geologic setting” from
this sentence.
Response: There is no objection to removing the phrase “other than the geologic setting”
under the discussion of the selected performance criterion for arsenic. However,
placement of the environmental covenant will prevent potable use of groundwater,
resulting in achievement of the onsite performance objective for arsenic.
5. Page 10, Application of Performance Objectives: Please remove the sentence “GE is
awaiting on comments on the proposed modifications.” The DERR has accepted the
proposed modifications to the on-site groundwater monitoring program by way of this
comment. The approach will be incorporated into the RAP along with the criteria in
Specific Comment #8.
Response: The identified phrase will be deleted and the text will be updated to reflect
UDERR’s approval of the modifications to the on-site groundwater monitoring program.
6. Page 11, Application of Performance Standards: Please revise the text to indicate that
long-term monitoring will be utilized to verify that the Performance Objectives have been

Response to Comments Groundwater RAP Addendum
-102 July 7,
met and will continue to be met.
Response: The comment is worded such that there will be no end to long-term
monitoring. Instead, the following text is proposed, “Sampling of select VOCs will
continue until data indicate the performance objectives have been met. At this point, in
general accordance with the USEPA guidance (1998*), an additional four semi-annual
groundwater monitoring events (two years) will be conducted to confirm that
concentrations of VOCs in groundwater remain below the Performance Objectives”.
* USEPA’s Technical Protocol for Evaluating Natural Attenuation of Chlorinated Solvents in Ground Water (1998)
7. Page 11, Application of Performance Standards: Please revise the text to clarify if the
95% UCL will represent individual well data or site-wide data. The DERR cannot accept
site-wide data for the entire plume to make decisions on whether the remedial goals have
been met. Individual well data will be evaluated.

Response: The text will be revised to indicate the “primary mechanism to evaluate Site-
wide achievement of the performance objective will be the calculation of an individual-
well specific 95% UCL for the COC of interest”. Additional supporting site-specific
information will be presented as appropriate to put the data in perspective, specifically
noting an exceedance at a single well in the interior of the site would not mean that the
site in its entirety would not meet the performance objective if site boundary wells meet
the performance objectives

8. Page 11, Application of Performance Standards, third paragraph: Please revise the text
to note that off-site groundwater monitoring will commence for a minimum of two years
and the data will then be evaluated before determining additional monitoring
requirements. The purpose of the off- site monitoring is to ensure there are no changing
conditions and unacceptable risk.

Response: The concluding paragraph on the Application of Performance Standards will
be revised to indicate GE Vernova will continue to monitor off-site groundwater for the
presence of 1,4-dioxane for a minimum of two years (four semi-annual events starting
with the March 2025 event) to determine additional monitoring requirements, or if the off-
site groundwater monitoring program can be terminated. In accordance with the
approved off-site groundwater monitoring program, select wells will also continue to be
monitored for chlorinated VOCs.

9. Page 12, Final Report and Certificate of Completion: Please submit a report with each
groundwater monitoring event. A Final Report should be submitted with a request for
closure once the cleanup goals have been met, there are no spikes in the data and the
plume is considered stable and decreasing. A Site Management Plan and Environmental
Covenant will need to be finalized prior to final closure to document the long term
obligations associated with the site.

Response to Comments Groundwater RAP Addendum
-102 July 7,

Response: At DERR’s request, a semi-annual monitoring report will be provided after
each groundwater monitoring event. The Final Report will be submitted with a request
for closure when the groundwater data meet the necessary requirements. It is
understood the Site Management Plan and Environmental Covenant will be finalized
prior to final closure to document any remaining long-term obligations associated with
the Site.

DERR Review Comments September 2024 Plume Analytics Report
Technical Comment:
Slide 30: The 1,4 Dioxane concentration in MW-3 for the September 2024 sampling event
is reported as 94 ug/L, which does not match the result from the on-site September 2024
Groundwater Monitoring Report. Please revise.

Response: DUP1-0191224 (duplicate) was collected from MW-3, and the result of the
duplicate was 94 ug/L. The September 2024 Plume Analytics Report included the
duplicate concentration since it was the highest concentration in MW-3 for the
groundwater monitoring event, and no revision of the report is warranted.

The process to achieve risk-based closure at this Site remains unresolved. Therefore,
groundwater monitoring under the accepted on- and off-site programs, with reports provided to
the DERR on the existing semi-annual schedule, will continue.

At this time, if requested by the DERR, the Groundwater RAP Addendum will be revised to
identify monitoring as the action selected to address 1,4-dioxane and MNA as the remedial
action for chlorinated VOCs. Alternative remedial actions are neither cost-effective nor
technically viable for 1,4-dioxane.

Please contact Brad Glisson at [e-mail] if you have any questions or comments
regarding this report or would like to set up a conference call to discuss.

Respectfully submitted,
WSP USA Inc.

Bradley K Glisson, CHMM Sara B. Mathews, CHMM
AVP - Project Manager AVP – Environmental Scientist

ATTACHMENT 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
9 5
0
9.6 11.51
13 12
1.096 0.365
0.0952 -0.815
0.844
0.764
0.339
0.316
12.19 12.01
12.17
0.893
0.72
0.353
0.279
118.3 78.95
0.0973 0.146
2130 1421
11.51 1.296
1335
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
12.26 12.42
0.832
0.859
0.345
0.252
2.262 2.439
2.565 0.0988
N/A 12.65
13.17 13.88
15.29
12.11 11.89
12.07 12.09
12.01 12
12.61 13.1
13.79 15.15
12.19
10 9
0
17 44
98 34
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
0.532 1.435
0.862
0.781
0.266
0.304
57.56 59.75
58.12
0.387
0.729
0.244
0.268
4.565 3.262
9.638 13.49
91.3 65.25
44 24.36
47.66
0.0267 45.06
60.24 63.71
0.96
0.869
0.214
0.241
2.833 3.671
4.585 0.496
64.07 64.83
74.34 87.53
113.5
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
56.17 59.6
55.72 63.64
70.59 56.1
66.19 76.24
90.19 117.6
57.56
10 10
0
34 64.8
150 60
32.11 10.15
0.496 2.389
0.715
0.781
0.311
0.304
83.41 89.7
84.69
0.726
0.728
0.244
0.267
6.373 4.528
10.17 14.31
127.5 90.56
64.8 30.45
69.61
0.0267 66.43
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
84.29 88.33
0.885
0.869
0.22
0.241
3.526 4.091
5.011 0.396
85.19 88.55
99.6 115
145.1
81.5 90.7
81.29 100.3
157.6 84
95.26 109.1
128.2 165.8
88.33
10 7
0
19 44.3
110 41
26.82 8.483
0.606 1.73
0.815
0.781
0.231
0.304
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
59.85 63.21
60.62
0.441
0.73
0.177
0.268
3.67 2.635
12.07 16.81
73.39 52.71
44.3 27.29
37.03
0.0267 34.76
63.05 67.18
0.915
0.869
0.181
0.241
2.944 3.649
4.7 0.554
68.5 67.7
78.41 93.29
122.5
58.25 61.6
57.45 68.55
124.6 57.9
69.75 81.28
97.27 128.7
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
9 7
4 5
4 3
0.5 0.2
1.6 0.597
0.25 55.56%
0.86 0.5
0.669 0.582
1.842 3.555
-0.257 0.504
0.768
0.687
0.392
0.413
0.5 0.168
0.435 N/A
0.812 N/A
0.776 N/A
1.004 1.232
1.55 2.172
0.554
0.659
0.387
0.396
4.904 1.393
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
39.23 11.14
0.86
0.01 0.388
1.6 0.01
0.542 1.4
0.384 0.33
1.009 1.174
6.913 5.942
0.0231
1.61 1.183
1.43 N/A
0.5 0.435
0.189 0.168
1.323 0.956
23.81 17.21
0.378 0.523
0.807 1.164
1.521 2.354
8.821 7.589
0.975 1.133
0.849
0.792
0.353
0.346
0.494 -1.026
0.465 0.822
0.782 0.76
0.837 1.029
1.153
-0.988 0.372
0.728 2.671
0.285 0.965
Adjusted Level of Significance (β)
Approximate Chi Square Value (5.94, α)Adjusted Chi Square Value (5.94, β)
Adjusted Chi Square Value (17.21, β)Approximate Chi Square Value (17.21, α)
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
0.285
0.471 -1.195
0.483 1.008
0.77 1.608
0.812
10 9
0
0.9 8.452
14 10.1
4.64 1.467
0.549 -0.541
0.89
0.781
0.251
0.304
11.14 10.6
11.1
0.731
0.735
0.262
0.27
2.147 1.57
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
42.94 31.39
8.452 6.746
19.59
0.0267 17.99
13.54 14.75
0.807
0.869
0.238
0.241
-0.105 1.884
2.639 0.891
23.04 17.5
21.22 26.37
36.5
10.87 10.5
10.68 10.77
10.42 10.6
12.85 14.85
17.61 23.05
11.14
10 10
0
8 60.33
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
46.16 14.6
0.765 0.41
0.907
0.781
0.168
0.304
87.09 86.36
87.4
0.308
0.739
0.176
0.271
1.5 1.117
40.23 54.03
30 22.33
60.33 57.09
12.59
0.0267 11.33
107 118.9
0.925
0.869
0.173
0.241
2.079 3.731
4.883 0.997
192 127.8
156.7 196.7
275.3
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
84.34 85.21
82.89 88.98
83.72 83.83
104.1 124
151.5 205.6
87.09
10 10
0
1.6 12.35
32.7 10.9
8.583 2.714
0.695 1.479
0.886
0.781
0.194
0.304
17.33 18.17
17.54
0.24
0.735
0.136
0.27
2.188 1.598
5.646 7.729
43.75 31.96
12.35 9.77
20.04
0.0267 18.41
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
19.7 21.43
0.93
0.869
0.176
0.241
0.47 2.268
3.487 0.817
28.47 23.37
28.09 34.64
47.51
16.81 17.72
16.57 19.45
40.17 16.84
20.49 24.18
29.3 39.35
17.33
8 7
1
5 3
5 2
1.8 0.2
6.1 0.597
3.127 37.5%
3.252 1.768
2.5 0.544
1.363 1.292
1.074 0.498
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
0.859
0.686
0.265
0.396
2.108 0.765
1.936 3.295
3.557 3.343
3.366 3.508
4.403 5.442
6.886 9.72
0.348
0.681
0.257
0.358
4.911 2.098
0.662 1.55
49.11 20.98
3.252
0.01 2.036
6.1 1.93
2.145 1.054
0.376 0.318
5.413 6.395
6.019 5.095
0.0195
1.196 0.788
8.672 13.16
Adjusted Level of Significance (β)
Approximate Chi Square Value (5.09, α)Adjusted Chi Square Value (5.09, β)
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
2.108 1.936
3.746 0.765
1.186 0.824
18.97 13.19
1.778 2.557
3.438 5.088
6.764 10.71
6.02 4.851
4.617 5.73
0.927
0.806
0.224
0.319
2.311 0.553
1.866 0.821
3.561 3.398
3.65 4.498
6.178
0.0677 1.07
1.346 4.323
0.532 23.87
1.346 4.323
0.532
2.095 -0.0555
2.083 1.639
3.49 86.52
3.557
Adjusted Chi Square Value (13.19, β)Approximate Chi Square Value (13.19, α)
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
9 9
1
8 1
8 1
0.2 0.597
12 0.597
18.56 11.11%
5.088 4.308
3.15 0.847
0.624 -1.342
1.119 1.316
0.881
0.749
0.251
0.333
4.544 1.46
4.098 6.811
7.26 6.867
6.946 7.968
8.925 10.91
13.66 19.07
0.333
0.734
0.209
0.301
1.122 0.784
4.535 6.486
17.95 12.55
5.088
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
0.01 4.523
12 2.6
4.37 0.966
0.602 0.475
7.517 9.518
10.83 8.554
0.0231
3.06 2.41
12.64 16.06
4.544 4.098
16.79 1.46
1.23 0.894
22.14 16.09
3.695 5.083
7.376 10.76
14.17 22.15
8.027 6.861
9.11 10.66
0.876
0.851
0.202
0.265
4.561 0.878
4.328 1.427
7.244 6.944
7.033 7.893
57.12
0.816 2.261
1.443 4.298
0.514 57.39
1.443 4.298
0.514
Adjusted Level of Significance (β)
Approximate Chi Square Value (8.55, α)Adjusted Chi Square Value (8.55, β)
Adjusted Chi Square Value (16.09, β)Approximate Chi Square Value (16.09, α)
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
4.334 1.455
7.242 63.21
7.26
10 9
0
2.3 14.27
22.6 15
7.295 2.307
0.511 -0.668
0.897
0.781
0.162
0.304
18.5 17.54
18.42
0.873
0.734
0.268
0.269
2.425 1.764
5.885 8.09
48.5 35.28
14.27 10.74
22.69
0.0267 20.95
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
22.19 24.03
0.759
0.869
0.31
0.241
0.833 2.438
3.118 0.829
34.69 28.13
33.87 41.82
57.46
18.06 17.33
17.8 17.91
17.46 17.74
21.19 24.33
28.68 37.22
18.5
10 9
7 3
6 3
0.889 0.2
2.7 0.597
0.401 30%
1.341 0.633
1.1 0.472
2.115 4.737
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
0.729
0.73
0.303
0.35
0.999 0.245
0.717 1.45
1.448 1.399
1.402 1.509
1.734 2.067
2.529 3.436
0.678
0.709
0.279
0.313
7.069 4.135
0.19 0.324
98.97 57.89
1.341
0.109 0.972
2.7 1
0.788 0.812
1.178 0.891
0.825 1.09
23.56 17.83
0.0267
9.265 8.213
1.869 2.109
0.999 0.717
0.514 0.245
1.94 1.425
Adjusted Level of Significance (β)
Approximate Chi Square Value (17.83, α)Adjusted Chi Square Value (17.83, β)
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
0.515 0.701
1.554 2.108
2.647 3.87
17.32 15.82
1.644 1.8
0.835
0.838
0.255
0.28
1.087 -0.0574
0.66 0.547
1.469 1.445
1.538 1.681
1.665
-0.328 0.72
0.89 2.882
0.304 2.518
0.89 2.882
0.304
0.999 -0.357
0.758 1.017
1.438 3.398
1.448
Adjusted Chi Square Value (28.50, β)Approximate Chi Square Value (28.50, α)
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
10 9
6 4
6 3
0.91 0.2
2.3 0.597
0.253 40%
1.577 0.503
1.6 0.319
0.129 -0.78
0.41 0.336
0.976
0.713
0.171
0.373
1.026 0.264
0.762 1.44
1.51 1.435
1.46 1.4
1.818 2.177
2.676 3.654
0.208
0.698
0.21
0.332
11.21 5.718
0.141 0.276
134.6 68.61
1.577
0.205 1.099
2.3 1.055
0.727 0.661
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
0.523 0.715
42 30.73
0.0267
19.07 17.49
1.77 1.93
1.026 0.762
0.581 0.264
1.811 1.334
36.21 26.68
0.567 0.769
1.607 2.2
2.781 4.101
15.91 14.48
1.721 1.891
0.97
0.826
0.202
0.298
1.191 0.0482
0.624 0.535
1.553 1.511
1.534 1.621
1.815
-0.398 0.672
1.017 3.139
0.352 3.269
1.017 3.139
0.352
1.016 -0.496
0.817 1.237
1.49 5.791
Adjusted Level of Significance (β)
Approximate Chi Square Value (30.73, α)Adjusted Chi Square Value (30.73, β)
Adjusted Chi Square Value (26.68, β)Approximate Chi Square Value (26.68, α)
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1.51
10 9
7 3
7 2
0.6 0.2
2.5 0.597
0.498 30%
1.574 0.706
1.57 0.448
-0.274 -1.147
0.344 0.541
0.944
0.73
0.172
0.35
1.162 0.285
0.834 1.605
1.684 1.594
1.631 1.656
2.017 2.404
2.941 3.996
0.387
0.71
0.235
0.313
4.694 2.778
0.335 0.567
65.72 38.89
1.574
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
0.0232 1.155
2.5 1.125
0.89 0.771
1.024 0.783
1.128 1.474
20.48 15.67
0.0267
7.728 6.781
2.342 2.669
1.162 0.834
0.695 0.285
1.941 1.426
38.83 28.51
0.599 0.815
1.808 2.452
3.079 4.5
17.33 15.83
1.912 2.093
0.887
0.838
0.26
0.28
1.219 -0.0456
0.813 0.772
1.69 1.63
1.637 1.717
2.551
-0.242 0.785
0.988 3.079
0.338 3.527
0.988 3.079
0.338
Adjusted Level of Significance (β)
Approximate Chi Square Value (15.67, α)Adjusted Chi Square Value (15.67, β)
Adjusted Chi Square Value (28.51, β)Approximate Chi Square Value (28.51, α)
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
0.893 1.224
1.67 6.487
1.684
10 10
9 1
9 1
0.4 0.2
17 0.2
27.95 10%
7.434 5.287
6.4 0.711
0.516 -0.455
1.633 1.124
0.942
0.764
0.193
0.316
6.711 1.745
5.203 9.471
9.91 9.31
9.582 10.25
11.95 14.32
17.61 24.08
0.342
0.735
0.187
0.284
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1.484 1.064
5.008 6.989
26.72 19.15
7.434
0.01 6.692
17 5.15
5.51 0.823
0.68 0.543
9.836 12.33
13.61 10.86
0.0267
4.485 3.799
16.2 19.13
6.711 5.203
27.07 1.745
1.664 1.231
33.27 24.62
4.034 5.451
10.6 14.68
18.7 27.88
14.32 12.98
11.54 12.73
0.852
0.859
0.228
0.252
6.733 1.383
5.456 1.323
9.896 9.623
9.741 10.39
51.14
Adjusted Level of Significance (β)
Approximate Chi Square Value (10.86, α)Adjusted Chi Square Value (10.86, β)
Adjusted Chi Square Value (24.62, β)Approximate Chi Square Value (24.62, α)
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1.399 3.974
0.469 62.86
1.399 3.974
0.469
6.701 1.239
5.498 1.635
9.888 154.4
9.91
10 10
0
1 6.343
11 6.84
3.509 1.11
0.553 -0.431
0.925
0.781
0.19
0.304
8.377 8.007
8.352
0.709
0.735
0.224
0.27
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
2.171 1.586
2.922 3.998
43.42 31.73
6.343 5.036
19.86
0.0267 18.24
10.14 11.03
0.794
0.869
0.24
0.241
0 1.6
2.398 0.873
16.62 12.88
15.58 19.33
26.7
8.168 7.885
8.031 8.175
7.913 8.03
9.672 11.18
13.27 17.39
8.377
10 10
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
9 1
0.5 0.2
6 0.2
2.628 10%
3.176 1.621
2.9 0.511
0.293 0.405
0.985 0.716
0.963
0.764
0.21
0.316
2.878 0.571
1.703 3.754
3.925 3.751
3.817 4.021
4.591 5.367
6.445 8.561
0.416
0.727
0.194
0.281
3.094 2.137
1.026 1.486
55.69 38.46
3.176
0.379 2.896
6 2.855
1.766 0.61
1.977 1.451
1.464 1.996
39.55 29.02
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
17.72 16.2
4.742 5.186
2.878 1.703
2.899 0.571
2.857 2.066
57.13 41.33
1.007 1.393
4.292 5.555
6.757 9.417
27.59 25.66
4.31 4.636
0.837
0.859
0.239
0.252
2.914 0.829
1.738 0.837
3.921 3.785
3.75 4.008
7.061
0.726 2.066
1.008 3.12
0.338 9.799
1.008 3.12
0.338
2.868 0.656
1.812 1.24
3.918 18.53
3.925
Adjusted Chi Square Value (41.33, β)Approximate Chi Square Value (41.33, α)
Adjusted Level of Significance (β)
Approximate Chi Square Value (29.02, α)Adjusted Chi Square Value (29.02, β)
1613
1614
1615